CP ADVISORS NEW YORK MILAN

‹ Back to list
CP Advisors assisted Capex in the acquisition of a minority stake in Medivis and For Health Pharma

Catania, Italy - 30 May 2018

CP Advisors assisted Capex in the acquisition of a minority stake in Medivis and For Health Pharma

Capex Pharma invests in the Medivis ophthalmic group. The investment holding Capex Pharma has announced the acquisition of a minority stake in the pharmaceutical group Medivis and in For Health Pharma.

Medivis is a pharmaceutical company focused on the research, production and marketing of ophthalmic products. Since its foundation in the early 2000s, Medivis has created innovative solutions for the maintenance and improvement of visual function and boasts over 14 international patents for the treatment of ocular pathologies.

The Company markets its products both in Italy, through a network of 30 dedicated scientific representatives, and abroad. Medivis has recently made available to Italian ophthalmologists a new nanoparticle ophthalmic solution containing low concentration iodopovidone (IODIM) for the protection of the ocular surface of patients subject to recurrent infections, as well as for preparing the eyes for ocular surgery.

In addition to IODIM, among the most representative products of Medivis’ portfolio are Cortivis (an eye drops based on hydrocortisone and hyaluronic acid, which today represents the first choice cortisone by the Italian ophthalmologist for all inflammations of the ocular surface and which holds a 10% market share in the ophthalmic cortisone segment) and Septavis (sodium hypochlorite-based kit solution, the only product on the market that sanitizes and disinfects the periocular area of ​​patients suffering from blepharitis). The partnership with Capex is aimed at accelerating the group's growth plan, which provides for the commercial launch of some products with important therapeutic uniqueness as early as 2019 and international expansion.

CP Advisors acted as exclusive financial advisor to Capex in the acquisition of investment in Medivis and For Health pharma


‹ Back to list